Retrospective evaluation of abdominal MRI imaging: prognostic value and therapy monitoring in patients with pancreatic neuroendocrine tumors receiving capecitabine and temozolomide (Cap/Tem) therapy

Retrospective evaluation of abdominal MRI imaging: prognostic value and therapy monitoring in patients with pancreatic neuroendocrine tumors receiving capecitabine and temozolomide (Cap/Tem) therapy - PNET_MRT_CAP/TEM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031783

Enrollment

100

Registered

2023-09-18

Start date

2023-07-27

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D44 D37.7 D47

Interventions

Group 1: All data used to confirm the diagnosis of pancreatic neuroendocrine tumor, lymph node, and distant metastases and to assess the degree of differentiation histopathologic data from bioptic or

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -> 18 years - NET pancreas - Abdominal MRI imaging before therapy and after Cap/Tem therapy, if applicable. - Cap/Tem therapy

Exclusion criteria

Exclusion criteria: - < 18 years - Incomplete examinations due to premature termination - Limited image quality due to artifacts

Design outcomes

Primary

Measure	Time frame
In this retrospective study, MRI data of patients with neuroendocrine pancreatic tumors will be analyzed. The following MR parameters will be retrospectively collected and analyzed anonymously directly before the start of Cap/Tem therapy: morphological criteria of the primarius, lymph node and liver metastases, such as size, vascularization, tumor burden and necrosis.	—

Secondary

Measure	Time frame
Functional parameters of the primarius, lymph node and distant metastases. Diffusion imaging Qualitative: presence of diffusion restriction, Quantitative: analysis of the primarius	—

Countries

Germany

Contacts

Public ContactChristine PD Dr. med. Schmid-Tannwald

Klinik und Poliklinik für Radiologie

Christine.Schmid-Tannwald@med.uni-muenchen.de089-440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026